Metastatic melanoma of the oral cavity showing prompt regression with the use of BRAF/MEK inhibitors

J Dermatol. 2024 Mar;51(3):e61-e62. doi: 10.1111/1346-8138.17019. Epub 2023 Oct 30.

Authors

Kazumasa Oya¹, Shoichiro Ishizuki¹, Shiori Yasunaga¹, Yasuhiro Fujisawa², Toshifumi Nomura¹

Affiliations

¹ Department of Dermatology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.
² Department of Dermatology, Ehime University Graduate School of Medicine, To-on, Japan.

PMID: 37904611
DOI: 10.1111/1346-8138.17019

No abstract available

Keywords: BRAF/MEK inhibitors; dabrafenib; immune checkpoint inhibitors; metastatic malignant melanoma; trametinib.

Publication types

Case Reports

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Disease-Free Survival
Humans
Melanoma* / pathology
Mitogen-Activated Protein Kinase Kinases
Mutation
Oximes / therapeutic use
Protein Kinase Inhibitors / therapeutic use
Proto-Oncogene Proteins B-raf / genetics
Pyridones / therapeutic use
Skin Neoplasms* / drug therapy
Skin Neoplasms* / pathology

Substances

Proto-Oncogene Proteins B-raf
Protein Kinase Inhibitors
Mitogen-Activated Protein Kinase Kinases
Pyridones
Oximes
BRAF protein, human